Description

Evuzamitide is a diagnostic imaging agent. Evuzamitide as a pan-amyloid radiotracer binding to amyloid deposits from multiple amyloidogenic proteins. Evuzamitide can be used for the research of early diagnosis of amyloid cardiomyopathy (CMP) and monitoring[1][2].—Cancer-programmed cell death–C202H351N71O62—-[1]Clerc OF, et al. Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET/CT Study. JACC Cardiovasc Imaging. 2023 Nov;16(11):1419-1432.–1420048-58-3–4766.39—-O=C(NCC(NCC(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN–Cancer–10 mM in DMSO–Others—-Others–Peptides